317 related articles for article (PubMed ID: 37845222)
21. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
22. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
[TBL] [Abstract][Full Text] [Related]
23. ELIOT: A platform to navigate the E3 pocketome and aid the design of new PROTACs.
Palomba T; Baroni M; Cross S; Cruciani G; Siragusa L
Chem Biol Drug Des; 2023 Jan; 101(1):69-86. PubMed ID: 35857806
[TBL] [Abstract][Full Text] [Related]
24. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Setia N; Almuqdadi HTA; Abid M
Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162
[TBL] [Abstract][Full Text] [Related]
25. Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.
Siepe DH; Picton LK; Garcia KC
ACS Synth Biol; 2023 Apr; 12(4):1081-1093. PubMed ID: 37011906
[TBL] [Abstract][Full Text] [Related]
26. Ubiquitin proteasome system in immune regulation and therapeutics.
Bhat SA; Vasi Z; Adhikari R; Gudur A; Ali A; Jiang L; Ferguson R; Liang D; Kuchay S
Curr Opin Pharmacol; 2022 Dec; 67():102310. PubMed ID: 36288660
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
28. Targeted Protein Degradation through E2 Recruitment.
Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK
ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189
[TBL] [Abstract][Full Text] [Related]
29. Targeted Degradation of 53BP1 Using Ubiquitin Variant Induced Proximity.
Aminu B; Fux J; Mallette E; Petersen N; Zhang W
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454069
[TBL] [Abstract][Full Text] [Related]
30. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
31. Identification of KLHDC2 as an efficient proximity-induced degrader of K-RAS, STK33, β-catenin, and FoxP3.
Röth S; Kocaturk NM; Sathyamurthi PS; Carton B; Watt M; Macartney TJ; Chan KH; Isidro-Llobet A; Konopacka A; Queisser MA; Sapkota GP
Cell Chem Biol; 2023 Oct; 30(10):1261-1276.e7. PubMed ID: 37591251
[TBL] [Abstract][Full Text] [Related]
32. Ubiquitin E3 ligases assisted technologies in protein degradation: Sharing pathways in neurodegenerative disorders and cancer.
Kaushik A; Parashar S; Ambasta RK; Kumar P
Ageing Res Rev; 2024 Apr; 96():102279. PubMed ID: 38521359
[TBL] [Abstract][Full Text] [Related]
33. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
34. E3-ligase knock down revealed differential titin degradation by autopagy and the ubiquitin proteasome system.
Müller E; Salcan S; Bongardt S; Barbosa DM; Krüger M; Kötter S
Sci Rep; 2021 Oct; 11(1):21134. PubMed ID: 34702928
[TBL] [Abstract][Full Text] [Related]
35. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
36. E3 ligase ligand chemistries: from building blocks to protein degraders.
Sosič I; Bricelj A; Steinebach C
Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989
[TBL] [Abstract][Full Text] [Related]
37. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
38. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
Kannt A; Đikić I
Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
[TBL] [Abstract][Full Text] [Related]
39. Current Challenges in Small Molecule Proximity-Inducing Compound Development for Targeted Protein Degradation Using the Ubiquitin Proteasomal System.
Radhakrishnan S; Hoff O; Muellner MK
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500212
[TBL] [Abstract][Full Text] [Related]
40. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
